Danaher Corporation $DHR Shares Bought by Hsbc Holdings PLC

Hsbc Holdings PLC raised its stake in Danaher Corporation (NYSE:DHR) by 5.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,443,380 shares of the conglomerate’s stock after buying an additional 73,115 shares during the quarter. Hsbc Holdings PLC’s holdings in Danaher were worth $274,998,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. EP Wealth Advisors LLC purchased a new position in shares of Danaher during the 2nd quarter worth $3,807,000. Northwestern Mutual Wealth Management Co. raised its holdings in Danaher by 303.7% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate’s stock valued at $56,777,000 after buying an additional 186,584 shares during the period. Puzo Michael J purchased a new stake in Danaher in the 2nd quarter valued at about $8,624,000. Madison Asset Management LLC acquired a new position in Danaher in the second quarter valued at about $85,451,000. Finally, First Nebraska Trust Co purchased a new position in Danaher during the second quarter worth about $14,106,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Down 0.1%

Shares of DHR opened at $207.46 on Monday. The company’s 50-day simple moving average is $201.74 and its 200-day simple moving average is $192.14. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a market capitalization of $145.84 billion, a PE ratio of 36.85, a P/E/G ratio of 2.59 and a beta of 0.78.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter in the previous year, the business posted $0.77 earnings per share. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. Analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DHR has been the subject of a number of recent analyst reports. Stifel Nicolaus dropped their price target on shares of Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a research report on Wednesday, July 22nd. Weiss Ratings raised shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th. Royal Bank Of Canada lifted their target price on shares of Danaher from $200.00 to $215.00 and gave the company an “outperform” rating in a report on Wednesday, July 22nd. Citigroup initiated coverage on Danaher in a research report on Tuesday, May 26th. They issued a “buy” rating and a $230.00 target price on the stock. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.